anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tooth loss results physiologically in a significant remodeling of the alveolar ridge. The bone resorption process begins immediately after extraction, leading to an average 40-60% decrease in the horizontal and vertical dimensions of the alveolar ridge, during the first 2 years (Amler 1969, Johnson 1969)1,2. The majority of post-extraction bone loss is more evident on the buccal aspect of the ridge (Pietrokovski \& Massler 1967)3 and occurs mainly within the first 3 months (Johnson 1969; Schropp et al. 2003)2,4. It is now known that crestal remodeling is strictly related to bundle bone resorption5 and that is more evident on the buccal plate where, especially in thin periodontal biotypes, can result in significant facial hard and soft tissue recessions. Bundle bone vascularization comes from periodontal ligament and it is interrupted by tooth extraction: for this reason bundle bone resorption and, consequent socket remodeling are impossible to prevent. Furthermore, modeling and remodeling of extraction sockets have a great variability in timing: a recent study (Trombelli et al. 2008) reports that bone organization and architecture is not completed 24 weeks after tooth extraction6.

In order to preserve ridge volumetry after extraction, many clinical techniques and various biomaterials have been suggested for grafting of post-extraction wounds7-12. Grafting of sockets provides stable clinical results but some studies demonstrate that, unless using a membrane, at histological examination most of the graft particles are encapsulated by fibrous tissue, especially in the coronal area 9,11. Recently, a study on an animal model (Araújo et al. 2009) reported that the presence of bone graft material in fresh extraction socket leads to a delayed healing response13.

On account of these observations, a novel surgical technique was presented in literature (Caiazzo et al. 2010)14, with the name of Buccal Plate Augmentation (BPA). After performing a gentle tooth extraction and verifying the integrity of the alveolar walls, BPA consists in placing a HA-based bone graft material over the intact buccal bone plate, underneath the soft tissues and the periosteum in a surgically created pouch with the aim to maintain or augment crestal volumetry and soft tissue aesthetics of the region. This approach allows for avoiding recession of the alveolar facial wall without interfering with the natural healing mechanism of the extraction socket, which is left undisturbed. To date, however, there is still no evidence regarding the most suitable biomaterial for maintaining predictably crestal volumetry and soft tissues contour overtime.
Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
Carefully consider the potential benefits and risks of INDOCIN and other treatment options before deciding to use INDOCIN. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].

After observing the response to initial therapy with indomethacin, the dose and frequency should be adjusted to suit an individual patient’s needs.

Adverse reactions generally appear to correlate with the dose of indomethacin. Therefore, every effort should be made to determine the lowest effective dosage for the individual patient.

Dosage recommendations for active stages of the following:
PURPOSE: A novel skin whitening compound is provided to further maintain skin whitening effect. CONSTITUTION: A whitening compound is denoted by chemical formula 1. In chemical formula 1, X is cobavalent bond or amino acid. An amino group of the amino acid is conjugated with carboxy group of caffeic acid. The amino acid is Gly, Ala, Leu, Ile, Pro, Hyp or Val. A whitening compound is denoted by chemical formula 2.
Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
PURPOSE:To provide the titled composition containing a granular dentifrice base and flavor-clathrating cyclodextrin granules coated with a substance composed of shellac, a glycerol fatty acid ester and a diluent, releasing the flavor component after a definite time and giving varied taste and flavor. CONSTITUTION:The titled composition can be produced by mixing a granular dentifrice base with flavor-clathrating cyclodextrin granules coated with a coating substance containing shellac, a glycerol fatty acid ester and a diluent at weight ratios of 10:(0.1-4.0):(10-30). The cyclodextrin granule has an average particle diameter of <=0.7mm and contains 10-40wt% coating substance. The flavor (e.g. cinnamon oil) is released from the flavor-clathrating cyclodextrin granule e.g. 60sec after application. The change of taste and flavor informs the lapse of proper period of application and, accordingly, it is not necessary to repeat the interruption of use to inspect the state of dissolution. The composition is free from defects such as the loss of desire to use caused by defoaming.
Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (\<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
Introduction: Nowadays, it is known that mechanical loading is essential to achieve tendon adaptations. So,if tendons are stimulated in the right way, positive changes will take part on the tendinous tissues increasing its capability to stand mechanical loading.In the last decade, low load blood flow restriction training has developed as an alternative methodto high load training, as some investigations have found a similar increase in force and hypertrophy between both training methods. Although, the evidence about tendon adaptations leading from low load blood flow restriction training is still very limited.Aim: The present study aims to study tendon temporary responses leading immediately after a low load blood flow restriction training and compare those adaptations with those leading from high load strength training.Design: A randomized case-control clinical trial will be conducted.Sample: The measurement of the sample size was done with theG\*Power 3.1.5 program and was based on the time-by-group interaction of a mixed variance analysis (ANOVA). With two groups and three measurement moments. The final sample size was constituted by 84 subjectsMethods:The 84 participants will be randomly allocated in two groups: a) Low load blood flow restriction training (n=42); b) high load strength training (n=42). The low load blood flow restriction training group will perform a strength training with an intensity equivalent to 30% 1RM with an occlusion pressure of 80% on the total restriction pressure assessed individually, whilst the other group will train with a load equivalent of 80% 1RM. Patellar tendon characteristics will be studied as morphometry and densitometry parameters and microcirculation pre, post immediate intervention and 24 hourspost intervention.
Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
This invention relates to a producing method of nano-propolis suspension. It contains nano-propolis particles involves adding and mixing 0.1% to 5% non ionic surfactant and 0.1% to 5% cationic surfactant under the condition of sonication into propolis extract respectively. Further, it creates base liquid, the base liquid is then added into 5 to 800 times volume of pure water under the condition of sonication and mixing before setting aside for a period of time before it becomes the propolis suspension containing nano propolis particles. Furthermore, it does not destruct the effective components and the structure of the propolis. Moreover, this producing method of nano-propolis suspension containing nano propolis particles is very reliable, easily operating, and cost effective. Eventually, it requires no complication machinery, and also environmental friendly.
INTRODUCTION: Lung cancer is a serious health problem with a high mortality rate. In the context of surgical management, minimally invasive approaches, including uniportal thoracoscopic techniques, offer potential benefits such as faster recovery and increased patient cooperation. The aim of this study was to compare the accessibility of the mediastinal lymph nodes between uniportal and multiportal thoracoscopic approaches and to verify whether the use of the uniportal approach affects the radicality of the lymphadenectomy.
METHODS: A comparative study conducted from January 2015 to July 2022 at the University Hospital Ostrava focused on evaluating the radicality of mediastinal lymphadenectomy between subgroups of patients undergoing surgery using the uniportal thoracoscopic approach and the multiportal thoracoscopic approach.
RESULTS: A total of 278 patients were included in the study. There were no significant differences in the number of available lymphatic stations between the subgroups. The mean number of lymph node stations removed was 6.46 in the left hemithorax and 6.50 in the right hemithorax. Thirty-day postoperative morbidity for the entire patient population was 24.5%, with 18.3% having minor complications and 3.6% having major complications. The overall mortality rate in the study population was 2.5%, with a statistically significant difference in mortality between uniportal and multiportal approaches (1.0% vs 6.4%, p=0.020).
CONCLUSIONS: The uniportal approach demonstrated comparable accessibility and lymph node yield to the multiportal approach. There was also no difference in postoperative morbidity between the two approaches. The study suggests the possibility of lower mortality after uniportal lung resection compared with multiportal lung resection, but this conclusion should be interpreted with caution.
The purpose of this clinical trial is to find out more about the side effects of immunotherapy with a form of radiation treatment for the cancer in the liver called Yttrium-90 RadioEmbolization (Y90-RE). An immunotherapy drug, durvalumab, will be given intravenously every 2 weeks. Investigators are studying what doses of durvalumab are safe for people in combination with this form of radiation treatment. Patients in this study will receive durvalumab, which is experimental and not approved by the U.S. Food and Drug Administration (FDA) for metastatic colorectal cancer. Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver.

The number of doses of the immunotherapy drug (range: 2 to 5) will depend on the cohort patients are assigned to. There is no placebo. Everyone on the study is treated with immunotherapy alongside Y90-RadioEmbolization.
The invention discloses a nucleic acid aptamer capable of recognizing HCV NS5A protein. The nucleic acid aptamer is a DNA (deoxyribonucleic acid) segment shown as the sequence SEQIDNO.5. Derivatives of the nucleic acid aptamer include RNA (ribonucleic acid) aptamer substituted by nucleotide, derivatives with framework modified, derivatives modified into peptide nucleic acid and derivatives connected with radioactive molecules. A screening method of the nucleic acid aptamer includes preparing hepatitis c virus NS5A protein with histidine labels, preparing pET200/D/LacZ protein with histidine labels; fixing the proteins, designing a random nucleic acid library; and finally screening the nucleic acid aptamer. The screening processes particularly include pre-processing a DNA library, reversely screening, positively screening and repeatedly screening and the like, and finally obtaining nucleic aptamer high in competition capability and optimized in sequence length. The nucleic acid aptamer and the derivatives thereof can be used for preparing detection reagent boxes or diagnosis reagent of the hepatitis c virus NS5A protein and also can be used for preparing reagents for suppressing propagation of hepatitis c virus in hepatic cells.
Patients receive 2 cycles of Capecitabine and Oxaliplatin (CapeOx) chemotherapy and evaluated with rectum Magnetic Resonance Imaging (MRI). Patients with more than 20% regression of maximum diameter of rectal tumor in MRI image will entry into next step of rectal artery infusion of Oxaliplatin and oral Capecitabine（1000mg/㎡）with anti-PD1 antibody（200mg）every 3 weeks for 2 cycles.Then those patients will receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME.
Each patient in this group will be administered intravenous Ibuprofen (400 mg/8 ml i.v. infusion) for pre-emptive analgesic effect 60 minutes before surgical third molar extraction. Before the surgery, each patient in this group will be given 0.3 mg/kg of ketamine (Ketalar 500 mg) in addition to 2 ml of local anesthesia.
The long head of the biceps (LHB) tendon is thought to be a common source of shoulder pain and dysfunction in patients with rotator cuff pathology.Tenotomy and tenodesis have been shown to produce favourable and comparable results in treating LHB lesions, but a controversy still exists regarding the treatment of choice. Some suggest that tenotomy should be reserved for older, low-demand patients, while tenodesis should be performed in younger patients and those who engage in heavy labor. Proponents of tenotomy suggest that this is a technically easy procedure that leads to easy rehabilitation and fast return to activity with a low complication and reoperation rate. However, those who support LHB tenodesis list good preservation of elbow flexion and supination strength, improvement of functional scores, elimination of pain, and avoidance of cosmetic deformity as benefits of the procedure. Alternatively, the LHB can be maintained in the joint without tenodesis or tenotomy. In fact, it has not been clearly shown that LHB tenodesis or tenotomy leads to improved outcomes compared to leaving the biceps tendon intact. The primary goal of this prospective multicenter randomized study is to evaluate whether LHB tenodesis grants superior post-operative functional outcomes compared to LHB tenotomy or leaving the LHB intact in patients undergoing rotator cuff repair (RCR) for an isolated full-thickness lesion of the supraspinatus. The primary goal of this prospective multicenter randomized study is to evaluate whether LHB tenodesis grants superior post-operative functional outcomes compared to LHB tenotomy or leaving the LHB intact in patients undergoing rotator cuff repair (RCR) for an isolated full-thickness lesion of the supraspinatus. The secondary goals are to determine whether there is a difference in post-operative functional outcomes between the LHB tenotomy group and the Intact LHB group, and if there is a difference in complication rates or patient satisfaction between the three groups.
SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a GLP-1 receptor agonist.

Insulin glargine is a human insulin analog produced by recombinant DNA technology utilizing a nonpathogenic laboratory strain of Escherichia coli (K12) as the production organism. The minimum potency of insulin glargine is NLT 15 units/mg. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added at the C-terminus of the B-chain. Insulin glargine has low aqueous solubility at neutral pH. At pH 4 insulin glargine is completely soluble. It has a molecular weight of 6.063 kDa.

Lixisenatide is a synthetic analogue of human GLP-1, which acts as a GLP-1 receptor agonist. Lixisenatide is a protein containing 44 amino acids, which is amidated at the C-terminal amino acid (position 44) and has a molecular weight of 4.8585 kDa.

SOLIQUA 100/33 (insulin glargine and lixisenatide) injection is a sterile, colorless to almost colorless solution for subcutaneous use. SOLIQUA 100/33 is supplied as a prefilled single-patient-use disposable pen contain 300 units of insulin glargine and 100 mcg of lixisenatide in 3 mL of a clear, colorless to almost colorless, sterile, and aqueous solution. Each mL contains 100 units of insulin glargine and 33 mcg of lixisenatide and the inactive ingredients: glycerol (20 mg), metacresol (2.7 mg), methionine (3 mg), zinc (30 mcg), and Water for Injection, USP. Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH. The approximate pH is 4.5.
A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
FIELD: pharmaceuticals.SUBSTANCE: group of inventions relates to the field of pharmaceuticals, namely to triterpene-based neuroprotective compositions, a pharmaceutical composition and a pharmaceutical dosage form for treatment of a neurological pathological condition, disease or disorder sensitive to triterpenes, as well as to methods for treatment of a neurological pathological condition, disease or disorder sensitive to triterpenes, to a time-delayed method for treatment of a stroke, to methods for preventing or reducing the occurrence rate of a neurological pathological condition, disease or disorder. The neuroprotective compositions comprise oleanolic acid or a pharmacologically acceptable salt thereof; ursolic acid or a pharmacologically acceptable salt thereof, and betulinic acid or a pharmacologically acceptable salt thereof in the ratio of 9 to 12:0.15 to 2.5:0.15 to 2.5. The pharmaceutical composition and the pharmaceutical dosage form comprise one or several pharmaceutical fillers and a triterpene-based composition. The methods for treatment of a neurological pathological condition, disease or disorder sensitive to triterpenes include introduction of a triterpene-based composition, or pharmaceutical composition, or pharmaceutical dosage forms in a dose of 0.1 to 100 mcg. The time-delayed method for treatment of a stroke includes, during the delayed period after the subject has suffered a stroke, introduction of a triterpene-based composition in a dose of 0.1 to 100 mcg; determination of the adequacy of the clinical response and/or therapeutic response of the subject to treatment with said composition; continued treatment with said composition or an increase or a reduction in said dose depending on the response. The methods for preventing or reducing the occurrence rate of a neurological pathological condition, disease or disorder in a population of subjects at risk of development thereof include introduction of a therapeutically effective amount of a triterpene-based composition to the subject.EFFECT: group of inventions ensures production of an improved neuroprotective composition containing a synergistic mixture of oleanolic acid, ursolic acid, betulinic acid, taken in a certain ratio - 9 to 12:0.15 to 2.5:0.15 to 2.5, wherein the composition ensures increased expression of ARE genes, increased neuroprotection, and reduced cellular toxicity compared to other closely related compositions based on triterpenes on an equimolar basis, in a wide range of doses.25 cl, 10 dwg, 14 tbl, 15 ex
The present invention discloses an ophthalmic composition for ophthalmic application(s) inclusive of Eye examination, surgeries carried out in the posterior chamber of the Eye like cataract surgery. The said composition comprises at least three active ingredients. The said ingredients may be inclusive of, but not restricted to, Epinephrine Bitartrate, Atropine Bisulphate, Xylocaine Hydrochloride and additives like, antioxidant compounds, buffers and the like. The said composition comes in a packaging container inclusive of sterile package such as vial/ampoule/prefilled syringes. The said composition can be directly injected in the Eye in order to bring about effective and speedy dilation of the pupil(s), in particular pupil(s) of relatively smaller dimension than normal pupil. The three active ingredients are mixed in a predefined percentage range in a predefined volume and the composition is supplied in a sterile package.
Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
This Randomized controlled trial was conducted at Department of General Surgery, at a tertiary teaching hospital , over duration of six months from 28th February 2020 to 27th August 2020. The calculated sample size was 60 i.e. 30 cases in each group, with 5% level of significance, 80% power of study and taking mean healing time with VAC therapy as 11.366 ± 3.488 days and with conventional dressing as 16.41 ± 3.104 days.6 Non-probability, consecutive sampling technique was used.

After taking permission from ethical review committee , total 60 patients who were presented in outpatient Department of Surgery, at a tertiary care Hospital, Karachi, fulfilling the inclusion criteria was selected. After informed, written consent, all selected cases were offered to pick up a slip from total mixed up slips (half-slips contained letter 'A' and other half slips contained letter 'B') and he/she was placed in that respective group. In group A patients, VAC dressing was applied while in group B conventional dressing was applied. In patients undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours. In patients with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily. All patients were followed regularly by the single researcher and mean healing time was noted in every patient of both groups as described in operational definition. This all data (age, gender, duration of ulcer, and size of ulcer, BMI, and healing time) was recorded on a specially designed Performa designed beforehand.